Dan Peer

Summary

Affiliation: Tel Aviv University
Country: Israel

Publications

  1. ncbi request reprint Systemic siRNA delivery to leukocyte-implicated diseases
    Dan Peer
    Department of Cell Research and Immunology, Laboratory for Nanomedicine, George S Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel
    Cell Cycle 8:853-9. 2009
  2. doi request reprint Hyaluronan-grafted particle clusters loaded with Mitomycin C as selective nanovectors for primary head and neck cancers
    Gideon Bachar
    Department of Otolaryngology Head and Neck Surgery, Rabin Medical Center, Petah Tiqwa and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
    Biomaterials 32:4840-8. 2011
  3. doi request reprint Special delivery: targeted therapy with small RNAs
    D Peer
    Laboratory of Nanomedicine, Department of Cell Research and Immunology, GS Wise Faculty of Life Science and Center for Nanoscience and Nanotechnology, Tel Aviv University, Tel Aviv, Israel
    Gene Ther 18:1127-33. 2011
  4. doi request reprint Induction of therapeutic gene silencing in leukocyte-implicated diseases by targeted and stabilized nanoparticles: a mini-review
    Dan Peer
    Laboratory of Nanomedicine, Dept of Cell Research and Immunology, George S Wise Faculty of Life Science, Israel
    J Control Release 148:63-8. 2010
  5. doi request reprint Structural profiling and biological performance of phospholipid-hyaluronan functionalized single-walled carbon nanotubes
    Ram Dvash
    Laboratory of Nanomedicine, Dept of Cell Research and Immunology, George S Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv 69978, Israel
    J Control Release 170:295-305. 2013
  6. doi request reprint Immunotoxicity derived from manipulating leukocytes with lipid-based nanoparticles
    Dan Peer
    Laboratory of Nanomedicine, Department of Cell Research and Immunology, George S Wise Faculty of Life Science, Tel Aviv University, Tel Aviv 69978, Israel
    Adv Drug Deliv Rev 64:1738-48. 2012
  7. doi request reprint Hyaluronan grafted lipid-based nanoparticles as RNAi carriers for cancer cells
    Dalit Landesman-Milo
    Laboratory of Nanomedicine, Department of Cell Research and Immunology, George S Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv 69978, Israel
    Cancer Lett 334:221-7. 2013
  8. pmc RNA inhibition highlights cyclin D1 as a potential therapeutic target for mantle cell lymphoma
    Shiri Weinstein
    Laboratory of Nanomedicine, Department of Cell Research and Immunology, George S Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel
    PLoS ONE 7:e43343. 2012
  9. doi request reprint eIF3c: a potential therapeutic target for cancer
    Rafi Emmanuel
    Laboratory of Nanomedicine, Department of Cell Research and Immunology, George S Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv 69978, Israel
    Cancer Lett 336:158-66. 2013
  10. ncbi request reprint Overcoming RNAi transduction in leukocytes using targeted and stabilized nanoparticles
    Rofa Elfakess
    Center for Nanoscience and Nanotechnology, George S Wise Faculty of Life Sciences, Department of Cell Research and Immunology, Laboratory of Nanomedicine, Tel Aviv University, Tel Aviv, Israel
    IDrugs 13:626-31. 2010

Collaborators

  • Miguel Weil
  • Doron Shabat
  • Arnon Nagler
  • Hong Liu
  • Tatiana I Novobrantseva
  • J Lieberman
  • Biana Godin
  • Meir Goldsmith
  • Shoshy Mizrahy
  • Shiri Weinstein
  • Dalit Landesman-Milo
  • Keren Cohen
  • Rafi Emmanuel
  • Ranit Kedmi
  • Ram Dvash
  • Leonardo J Solmesky
  • Noa Ben-Arie
  • Einat Kisin-Finfer
  • Liya Dahan
  • Mark A Behlke
  • Ala Daka
  • S Moein Moghimi
  • Gideon Bachar
  • Rofa Elfakess
  • Rachel Cohen-Kupiec
  • Ilia Rivkin
  • Orit Redy
  • Shani Leviatan-Ben-Arye
  • Lilach Abramovitz
  • Srimeenakshi Srinivasan
  • Shani Leviatan Ben-Arye
  • Emily Brown
  • Artium Khatchatouriants
  • Vered Morad
  • Lingyan Huang
  • Peter P Wibroe
  • Bruria Witenberg
  • Sarit Tabak
  • Sigalit Leibovitch
  • Shalhevet Azriel
  • Avigdor Abraham
  • Andrew G Sprague
  • Ashley M Jacobi
  • Aviram Mizrachi
  • Dalit Landsman-Milo
  • Thomas Shpitzer
  • Michal Shuman
  • Sabina Rebe Raz
  • Maria G E G Bremer
  • Roy Hod
  • Martin Hasgaard
  • Neta Soffer-Tsur
  • Odelia Katz
  • Raphael Feinmesser
  • Jacob Koffler
  • Dina Melikhov
  • Gal Kantor
  • Rimona Margalit

Detail Information

Publications26

  1. ncbi request reprint Systemic siRNA delivery to leukocyte-implicated diseases
    Dan Peer
    Department of Cell Research and Immunology, Laboratory for Nanomedicine, George S Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel
    Cell Cycle 8:853-9. 2009
    ....
  2. doi request reprint Hyaluronan-grafted particle clusters loaded with Mitomycin C as selective nanovectors for primary head and neck cancers
    Gideon Bachar
    Department of Otolaryngology Head and Neck Surgery, Rabin Medical Center, Petah Tiqwa and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
    Biomaterials 32:4840-8. 2011
    ..These results demonstrate the specificity of the nanovectors towards head and neck cancers, which might be applicable as future therapy to many CD44-expressing tumors...
  3. doi request reprint Special delivery: targeted therapy with small RNAs
    D Peer
    Laboratory of Nanomedicine, Department of Cell Research and Immunology, GS Wise Faculty of Life Science and Center for Nanoscience and Nanotechnology, Tel Aviv University, Tel Aviv, Israel
    Gene Ther 18:1127-33. 2011
    ..However, delivering small RNAs into specific tissues and cells is still a hurdle. Here, we review recent progress in overcoming systemic, local and cellular barriers to RNA drug delivery, focusing on strategies for targeted uptake...
  4. doi request reprint Induction of therapeutic gene silencing in leukocyte-implicated diseases by targeted and stabilized nanoparticles: a mini-review
    Dan Peer
    Laboratory of Nanomedicine, Dept of Cell Research and Immunology, George S Wise Faculty of Life Science, Israel
    J Control Release 148:63-8. 2010
    ..Finally, we discuss our strategies to target subsets of leukocytes using integrin-targeted and stabilized nanoparticles (I-tsNPs)...
  5. doi request reprint Structural profiling and biological performance of phospholipid-hyaluronan functionalized single-walled carbon nanotubes
    Ram Dvash
    Laboratory of Nanomedicine, Dept of Cell Research and Immunology, George S Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv 69978, Israel
    J Control Release 170:295-305. 2013
    ..Taken together, these results suggest an immune protective mechanism by the PL-HA coating that could provide future therapeutic benefit. ..
  6. doi request reprint Immunotoxicity derived from manipulating leukocytes with lipid-based nanoparticles
    Dan Peer
    Laboratory of Nanomedicine, Department of Cell Research and Immunology, George S Wise Faculty of Life Science, Tel Aviv University, Tel Aviv 69978, Israel
    Adv Drug Deliv Rev 64:1738-48. 2012
    ..Herein, I describe general concepts of the immune system and the interaction of subsets of leukocytes with LNPs. Finally, I detail the different immune toxicities reported and propose ways to manipulate leukocytes' functions using LNPs...
  7. doi request reprint Hyaluronan grafted lipid-based nanoparticles as RNAi carriers for cancer cells
    Dalit Landesman-Milo
    Laboratory of Nanomedicine, Department of Cell Research and Immunology, George S Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv 69978, Israel
    Cancer Lett 334:221-7. 2013
    ..The HA-LNPs may offer an alternative approach to cationic lipid-based formulations for RNAi delivery into cancer cells in an efficient and safe manner...
  8. pmc RNA inhibition highlights cyclin D1 as a potential therapeutic target for mantle cell lymphoma
    Shiri Weinstein
    Laboratory of Nanomedicine, Department of Cell Research and Immunology, George S Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel
    PLoS ONE 7:e43343. 2012
    ..These results mark cyclin D1 as a target for mantle cell lymphoma and emphasize the therapeutic potential hidden in its silencing...
  9. doi request reprint eIF3c: a potential therapeutic target for cancer
    Rafi Emmanuel
    Laboratory of Nanomedicine, Department of Cell Research and Immunology, George S Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv 69978, Israel
    Cancer Lett 336:158-66. 2013
    ..Taking together, our results emphasize the importance of seeking ubiquitously expressed housekeeping genes such as eIF3c rather than tumor associated overexpressed genes as therapeutic targets for the heterogeneous malignancies...
  10. ncbi request reprint Overcoming RNAi transduction in leukocytes using targeted and stabilized nanoparticles
    Rofa Elfakess
    Center for Nanoscience and Nanotechnology, George S Wise Faculty of Life Sciences, Department of Cell Research and Immunology, Laboratory of Nanomedicine, Tel Aviv University, Tel Aviv, Israel
    IDrugs 13:626-31. 2010
    ....
  11. doi request reprint Integrin-targeted nanoparticles for siRNA delivery
    Noa Ben-Arie
    Laboratory of Nanomedicine, Department of Cell Research and Immunology, George S Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel
    Methods Mol Biol 757:497-507. 2012
    ....
  12. doi request reprint Assessing cellular toxicities in fibroblasts upon exposure to lipid-based nanoparticles: a high content analysis approach
    Leonardo J Solmesky
    Cell Screening Facility for Personalized Medicine, Laboratory for Neurodegenerative Diseases and Personalized Medicine, Tel Aviv University, Tel Aviv 69978, Israel
    Nanotechnology 22:494016. 2011
    ..The use of HCA opens new avenues in understanding cellular response and nanotoxicity and may become a valuable tool for screening safe materials for drug delivery and tissue engineering...
  13. doi request reprint Modulation of drug resistance in ovarian adenocarcinoma using chemotherapy entrapped in hyaluronan-grafted nanoparticle clusters
    Keren Cohen
    Laboratory of Nanomedicine, Department of Cell Research and Immunology, George S Wise Faculty of Life Sciences, Department of Materials Sciences and Engineering, Faculty of Engineering, Center for Nanoscience and Nanotechnology, and School of Chemistry, Tel Aviv University, Tel Aviv 69978, Israel
    ACS Nano 8:2183-95. 2014
    ..Taken together, these results demonstrated that GAGs might serve as an efficient platform for delivery of therapeutic payloads by bypassing P-gp-mediated multidrug resistance. ..
  14. doi request reprint Altering the immune response with lipid-based nanoparticles
    Dalit Landesman-Milo
    Laboratory of Nanomedicine, Dept of Cell Research and Immunology, George S Wise Faculty of Life Science, Tel Aviv University, Tel Aviv 69978, Israel Center for Nanoscience and Nanotechnology, Tel Aviv University, Tel Aviv, 69978, Israel
    J Control Release 161:600-8. 2012
    ..By understanding the interactions of LNPs with the innate and the adaptive arms of the immune system it might be possible to attain improved therapeutic benefits and to avoid immune toxicity...
  15. doi request reprint Grand challenges in modulating the immune response with RNAi nanomedicines
    Meir Goldsmith
    Laboratory of Nanomedicine, Department of Cell Research and Immunology, George S Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, 69978, Israel
    Nanomedicine (Lond) 6:1771-85. 2011
    ..Finally, we discuss the hurdles and potential opportunities for in vivo manipulation of the immune response utilizing RNAi nanomedicines...
  16. doi request reprint A daunting task: manipulating leukocyte function with RNAi
    Dan Peer
    Laboratory of Nanomedicine, Department of Cell Research and Immunology, George S Wise Faculty of Life Science, Tel Aviv, Israel
    Immunol Rev 253:185-97. 2013
    ....
  17. doi request reprint Polysaccharides as building blocks for nanotherapeutics
    Shoshy Mizrahy
    Laboratory of Nanomedicine, Dept of Cell Research and Immunology, Georg S Wise Faculty of Life Science, Tel Aviv University, Tel Aviv, 69978, Israel
    Chem Soc Rev 41:2623-40. 2012
    ....
  18. doi request reprint Hyaluronan-coated nanoparticles: the influence of the molecular weight on CD44-hyaluronan interactions and on the immune response
    Shoshy Mizrahy
    Laboratory of Nanomedicine, Dept of Cell Research and Immunology, Georg S Wise Faculty of Life Science, Tel Aviv University, Tel Aviv 69978, Israel
    J Control Release 156:231-8. 2011
    ....
  19. doi request reprint Tumor targeting profiling of hyaluronan-coated lipid based-nanoparticles
    Shoshy Mizrahy
    Laboratory of Nanomedicine, Department of Cell Research and Immunology, George S Wise Faculty of Life Science, Tel Aviv University, Tel Aviv 69978, Israel
    Nanoscale 6:3742-52. 2014
    ..Taken together, these findings have major implications for the use of high molecular weight HA in nanomedicine as a selective and safe active cellular targeting moiety. ..
  20. pmc SNP detection in mRNA in living cells using allele specific FRET probes
    Liya Dahan
    Department of Cell Research and Immunology, Tel Aviv University, Tel Aviv, Israel Center for Nanoscience and Nanotechnology, Tel Aviv University, Tel Aviv, Israel
    PLoS ONE 8:e72389. 2013
    ..This approach promotes in vivo molecular imaging methods and could further be applied in cancer diagnosis and theranostic strategies. ..
  21. doi request reprint RNAi-based nanomedicines for targeted personalized therapy
    Ala Daka
    Laboratory of Nanomedicine, Department of Cell Research and Immunology, George S Wise Faculty of Life Science, Israel
    Adv Drug Deliv Rev 64:1508-21. 2012
    ....
  22. pmc IKAP/hELP1 down-regulation in neuroblastoma cells causes enhanced cell adhesion mediated by contactin overexpression
    Rachel Cohen-Kupiec
    Department of Cell Research and Immunology, Tel Aviv University, Tel Aviv, Israel
    Cell Adh Migr 4:541-50. 2010
    ..We show that Contactin expression is related to IKAP expression, suggesting that IKAP regulates Contactin levels for appropriate cell-cell adhesion that could modulate neuronal growth of PNS neurons during development...
  23. doi request reprint The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation
    Ranit Kedmi
    Laboratory of Nanomedicine, Department of Cell Research and Immunology, George S Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv 69978, Israel
    Biomaterials 31:6867-75. 2010
    ..These results suggest that a careful attention must be made when different types of (+)NPs are being developed as nanotherapeutics...
  24. doi request reprint RNAi nanomedicines: challenges and opportunities within the immune system
    Shiri Weinstein
    Department of Cell Research and Immunology, George S Wise Faculty of Life Science, Israel
    Nanotechnology 21:232001. 2010
    ..This review will present the recent progress with the challenges and opportunities in this emerging field, focusing mostly on the in vivo applications with special emphasis on the strategies for RNAi delivery into immune cells...
  25. doi request reprint Precision nanomedicine in neurodegenerative diseases
    Meir Goldsmith
    Laboratory of Nanomedicine, Department of Cell Research and Immunology, George S Wise Faculty of Life Science, Department of Material Science and Engineering, and the Center for Nanoscience and Nanotechnology, Tel Aviv University, Tel Aviv 69978, Israel
    ACS Nano 8:1958-65. 2014
    ..The next generation strategies will most likely be more cell-type-specific. Devising these strategies to target the brain may ultimately become a novel therapeutic modality to treat neurodegenerative diseases. ..
  26. doi request reprint Paclitaxel-clusters coated with hyaluronan as selective tumor-targeted nanovectors
    Ilia Rivkin
    Department of Biochemistry and Molecular Biology, George S Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel
    Biomaterials 31:7106-14. 2010
    ..Our findings suggest GAGs merit further investigation as vehicles for taxanes, and may be applicable as carriers in other therapeutic settings...